How Much Does Zepbound Cost in North Dakota in 2026?

Zepbound Retail Price in North Dakota

The manufacturer list price set by Eli Lilly for Zepbound is $1,059 per month across all dose strengths (2.5 mg through 15 mg), and North Dakota retail pharmacies reflect this same figure for cash-pay customers in 2026. This price applies whether you fill at an independent pharmacy in Fargo, a chain location in Bismarck, or anywhere else in the state.

That $1,059 represents the wholesale acquisition cost passed through to patients without insurance coverage or discount programs. Tirzepatide, the active ingredient in Zepbound, is a dual GIP/GLP-1 receptor agonist that earned FDA approval for chronic weight management in November 2023. In the SURMOUNT-1 trial (N=2,539), participants on the 15 mg dose achieved 22.5% mean body weight reduction at 72 weeks compared to 2.4% with placebo. The clinical magnitude of that result is part of what drives both the demand and the price.

Unlike some states where pharmacy benefit manager (PBM) negotiations produce modest cash-price variation between retailers, North Dakota's smaller pharmacy market tends to cluster tightly around that $1,059 figure. Discount platforms like GoodRx or RxSaver may shave $20 to $80 off this price at select locations, but the savings are inconsistent and should not be relied on as a long-term strategy.

North Dakota Medicaid and Zepbound

North Dakota Medicaid does not cover Zepbound for chronic weight management as of May 2026. This is consistent with the majority of state Medicaid programs, which classify GLP-1 receptor agonists prescribed for obesity as elective or non-formulary medications.

The distinction matters because tirzepatide is also marketed as Mounjaro for type 2 diabetes, and North Dakota Medicaid does cover Mounjaro under that indication. Same molecule, different FDA label, different coverage decision. If a patient carries a concurrent type 2 diabetes diagnosis, the prescriber may be able to obtain coverage through the Mounjaro formulary pathway. This does not apply to patients whose sole indication is weight management.

North Dakota's Department of Health and Human Services publishes its preferred drug list (PDL) quarterly. Past legislative sessions have seen bills proposing anti-obesity medication coverage mandates, but none have passed into law. The Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy recommends that payers cover FDA-approved anti-obesity medications as part of comprehensive treatment, a position echoed by the American Association of Clinical Endocrinology.

Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine and a co-author of the Endocrine Society guideline, has stated: "Obesity is a chronic, relapsing disease that requires long-term treatment. Excluding FDA-approved pharmacotherapy from coverage is inconsistent with how we treat every other chronic condition."

Patients denied Medicaid coverage in North Dakota can file a formal appeal or request a prior authorization exception if they have documented comorbidities such as obstructive sleep apnea, type 2 diabetes risk factors, or cardiovascular disease.

Commercial Insurance Coverage in North Dakota

Coverage for Zepbound among commercial insurance plans in North Dakota varies by carrier and plan tier. Blue Cross Blue Shield of North Dakota (BCBSND), Sanford Health Plan, and Medica are the largest carriers operating in the state. Some employer-sponsored plans through these carriers have added GLP-1 coverage for weight management, while individual marketplace plans generally have not.

The determining factor is almost always the pharmacy benefit, not the medical benefit. Patients should call the number on the back of their insurance card and ask two specific questions: (1) "Is Zepbound on my plan's formulary for the obesity/weight management indication?" and (2) "What is my specialty tier copay or coinsurance?"

When Zepbound is covered, it typically sits on a specialty tier with coinsurance of 25% to 50%, translating to $265 to $530 per month before any manufacturer copay assistance. Plans that require step therapy may mandate a trial of an older agent (phentermine, naltrexone-bupropion) before approving tirzepatide.

A 2024 analysis published in JAMA Network Open found that only 27% of commercially insured patients who were prescribed a GLP-1 receptor agonist for obesity had their first fill covered without restriction. Prior authorization requirements, step therapy, and quantity limits were the three most common barriers.

The Eli Lilly Savings Card

Eli Lilly's Zepbound Savings Card program is active in North Dakota and can reduce out-of-pocket costs to $25 per monthly fill for patients with qualifying commercial insurance. The program is not available to patients on Medicare, Medicaid, Tricare, or other government-funded plans.

Eligibility requirements: you must have commercial insurance that covers Zepbound (even with high cost-sharing), a valid prescription from a licensed provider, and you must fill at a participating pharmacy. The card covers the difference between your plan's copay or coinsurance and the $25 patient responsibility, up to a maximum benefit per fill.

Patients without any insurance coverage can access a separate Lilly direct-pay program. Through LillyDirect, uninsured patients may obtain Zepbound at a reduced cash price, though specific pricing fluctuates and should be confirmed at the time of enrollment. The program ships directly to the patient and is available to North Dakota residents.

One practical note: the savings card resets annually and Lilly can modify or discontinue terms at any time. Patients should not assume the $25 copay will persist indefinitely when budgeting for long-term treatment. The SURMOUNT-1 trial demonstrated that weight regain occurs after discontinuation, which means most patients who respond to tirzepatide will need to remain on therapy long-term to maintain results.

Compounded Tirzepatide in North Dakota

Compounded tirzepatide is available in North Dakota through state-licensed 503A compounding pharmacies at approximately $249 per month. This represents a 76% reduction compared to the brand-name retail price.

The legal basis: under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed compounding pharmacy can prepare a compounded version of an FDA-approved drug when it is based on a valid patient-specific prescription from a licensed prescriber. The compounder must use pharmaceutical-grade tirzepatide base or API (active pharmaceutical ingredient) sourced from an FDA-registered supplier.

The FDA's current position on compounded GLP-1 receptor agonists has evolved. As of early 2026, the FDA has stated that tirzepatide is no longer on its drug shortage list, which may affect the legal framework for some compounders who had been operating under the shortage exception. However, 503A pharmacies operating under traditional patient-specific prescriptions in North Dakota continue to compound tirzepatide where prescriber-patient relationships exist.

Patients considering compounded tirzepatide should verify three things. First, confirm the pharmacy holds a valid North Dakota Board of Pharmacy license. Second, ask whether the pharmacy undergoes third-party potency and sterility testing on each batch. Third, request a certificate of analysis (COA) for the API used. The FDA's BeSafeRx program provides resources for verifying pharmacy legitimacy, though it focuses primarily on online pharmacies.

Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital, has noted: "Compounded tirzepatide may offer a cost-accessible entry point, but patients and prescribers need to ensure the source pharmacy meets USP 797 sterile compounding standards. The dose accuracy and sterility of the product are non-negotiable safety considerations."

Pricing at 503A pharmacies in North Dakota varies by dose. The $249 figure reflects an average across commonly prescribed maintenance doses (5 mg to 10 mg weekly). Titration-phase doses (2.5 mg) may be slightly less expensive.

Telehealth Access in North Dakota

North Dakota permits telehealth prescribing of Zepbound, making it possible for residents in rural areas to obtain a prescription without an in-person visit. This is significant in a state where 44 of 53 counties are classified as rural, and many residents live an hour or more from the nearest obesity medicine specialist.

Several national telehealth platforms serve North Dakota patients for GLP-1 prescriptions, including Ro, Found, Calibrate, and HealthRX. The telehealth consultation itself typically costs $50 to $150 for the initial evaluation and $30 to $75 for follow-up visits, depending on the platform.

North Dakota's telehealth prescribing rules, governed by the North Dakota Board of Medicine, require that the prescribing provider establish a valid provider-patient relationship. This can be done via synchronous video visit. Audio-only consultations may satisfy the requirement in some circumstances, but a video evaluation is the most straightforward path.

Patients using telehealth for Zepbound should ensure their provider orders baseline labs (hemoglobin A1c, lipid panel, thyroid function, and renal function) before initiating therapy and monitors for common adverse effects including nausea, which occurred in 24% to 33% of participants in SURMOUNT-1 depending on dose, as well as less common but serious risks such as pancreatitis and gallbladder events.

Discount Programs and Patient Assistance

Beyond the Lilly savings card, several additional programs can reduce Zepbound costs for North Dakota residents.

Manufacturer patient assistance (Lilly Cares Foundation): For uninsured patients with household income below 400% of the federal poverty level, Lilly Cares may provide Zepbound at no cost. The application requires documentation of income and a prescription from a licensed provider.

Pharmacy discount cards: GoodRx, SingleCare, and similar platforms occasionally offer Zepbound coupons at North Dakota pharmacies. These discounts are modest ($20 to $80 off list price) and vary by location and by week. They cannot be combined with the Lilly savings card or insurance.

Employer wellness programs: Some large North Dakota employers, including Sanford Health and the state government, have begun offering weight management drug coverage as part of enhanced wellness benefits. Check with your HR department.

Clinical trials: The ClinicalTrials.gov registry lists active tirzepatide studies that may provide the drug at no cost. A search filtered to North Dakota or neighboring states (Minnesota, Montana, South Dakota) may yield options, particularly for patients who have not yet started therapy.

The most cost-effective path for most North Dakota residents: confirm insurance coverage first, apply the Lilly savings card if eligible, and consider compounded tirzepatide through a licensed 503A pharmacy if brand-name Zepbound remains financially prohibitive. Patients qualifying for Lilly Cares should apply early, as processing times can reach 4 to 6 weeks.

Zepbound Dosing and What to Expect

Zepbound is administered as a once-weekly subcutaneous injection using a prefilled single-dose pen. The FDA-approved dosing schedule starts at 2.5 mg weekly for the first 4 weeks (a tolerability dose, not a therapeutic dose), then increases to 5 mg weekly. From there, the dose can be escalated in 2.5 mg increments every 4 weeks to a maximum of 15 mg weekly, based on tolerability and clinical response.

In SURMOUNT-1, mean weight loss by dose at 72 weeks was: 5 mg, 16.0%; 10 mg, 21.4%; 15 mg, 22.5% (vs. 2.4% placebo). The SURMOUNT-2 trial, conducted specifically in adults with type 2 diabetes and obesity, showed 12.8% and 14.7% weight loss at the 10 mg and 15 mg doses, respectively.

The cost per month does not change with dose escalation. Whether a patient is on 2.5 mg or 15 mg, the list price remains $1,059, and the savings card copay remains $25 (if eligible). This is an important budgeting consideration: the financial commitment is fixed from month one.

Common side effects are gastrointestinal. Nausea affects roughly one in three patients during titration but tends to diminish after 8 to 12 weeks at a stable dose. Constipation, diarrhea, and injection-site reactions also occur. The FDA label carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies, and Zepbound is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Patients in North Dakota filling Zepbound for the first time should plan to pick up the medication within 24 hours of pharmacy notification, as the drug requires refrigeration at 36°F to 46°F (2°C to 8°C) until first use. An unopened pen can be stored at room temperature (up to 86°F / 30°C) for up to 30 days.